We have patients who, sadly, are hoping their panel comes back from their lab work and shows that they have diabetes so that they can get coverage for medication, Zucchi added
Overall, GLP-1 RAs were associated with a significantly lower risk of cerebrovascular events compared with placebo and active comparators (risk ratio [RR] 0.83
In a Phase II trial, pelacarsen reduced Lp(a) levels by 3558% depending on the dose, with no significant differences in safety indicators compared with the placebo
At the same time, it is important to consider how semaglutide might affect the digestive system
PlushCare and Oral GLP-1s PlushCares clearest oral option is Rybelsus (oral semaglutide)
These are different conditions with different mechanisms